International American Capital Inc. United States

International American Capital Inc. (IAC), an Affiliate of the SCS Group, is a full service independent corporate and family consulting firm. IAC has a long standing tradition dedicated to wealth management for institutions and families. This focus allows us to achieve the highest level of expertise and excellence. IAC is independent advisory firm, free of any conflicts of interest that may arise in larger financial institutions. IAC  enjoys total financial independence and complete autonomy in the decision making process. We therefore offer our clients independent, trusted unbiased advise.  

The principals if IAC have over 70 years of experience in the financial services industry. IAC is led by entrepreneurs. As such, we have a better understanding of our clients' needs and expectations. The flexibility and availability of its principals to all our clients enables IAC to respond rapidly to customized solutions. Our principals are currently licensed with the SEC, FINRA and the CFTC. he CFTC. 
Mr Michael Segal
President 

Intl law. United States

BRIGITTE GAMBINI
Avocat à la Cour, Paris Licensed Legal Consultant, New York Référent du Barreau de Paris à New York / Representative of the Paris Bar in New York 

Intrexon Corporation United States

Intrexon applies engineering principles to biology to enable products in the health, food, energy, consumer and environmental industries.  Utilizing our advanced technologies, we work with researchers, developers and marketers to design, create or modify molecules, cells, organisms and processes to solve important problems in the living world.

Olivier Jarry
SVP Consumer Sector 

Ipsen Bioscience, Inc. United States

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: neurology / Dysport®, endocrinology / Somatuline® and uro-oncology / Decapeptyl®. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. The Group has close to 4,600 employees worldwide. 

Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visitwww.ipsen.com and www.ipsenus.com.

Website:
www.ipsen.com
Dr Girish Aakalu
Vice President Scientific Affairs, North America